Browse
Submit Data
Databases
API
Help

Metabolomics,Unknown,Transcriptomics,Genomics,Proteomics

Dataset Information

5 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

Expression profiling of PaTu8988s and PaTu8988t cell lines

ABSTRACT: We used microarray to look at the genes deregulated in PaTu8988s (adenovirus insensitive) and PaTu8988t (adenovirus sensitive) cell lines PaTu8988s and PaTu8988t are pancreatic cell lines derived from the same patient and show significant responses to oncolytic adenoviruses. The different response to adenovirus in these cell lines is not related to the previously known mechanisms that affect adenovirus infection. The two cell lines represent represent a "suitable" model to screen tumour-associated genes affecting the potency of aoncolytic adenovirus. RNA was extracted and hybridized on Affymetrix microarrays.

ORGANISM(S): Homo sapiens

SUBMITTER: yaohe Wang

PROVIDER: E-GEOD-14701 | biostudies-arrayexpress |

REPOSITORIES: biostudies-arrayexpress

ACCESS DATA

Json Xml

Publications

CEACAM6 attenuates adenovirus infection by antagonizing viral trafficking in cancer cells.

Wang Yaohe Y Gangeswaran Rathi R Zhao Xingbo X Wang Pengju P Tysome James J Bhakta Vipul V Yuan Ming M Chikkanna-Gowda C P CP Jiang Guozhong G Gao Dongling D Cao Fengyu F Francis Jennelle J Yu Jinxia J Liu Kangdong K Yang Hongyan H Zhang Yunhan Y Zang Weidong W Chelala Claude C Dong Ziming Z Lemoine Nick N

The Journal of clinical investigation 20090601 6

The changes in cancer cell surface molecules and intracellular signaling pathways during tumorigenesis make delivery of adenovirus-based cancer therapies inefficient. Here we have identified carcinoembryonic antigen- related cell adhesion molecule 6 (CEACAM6) as a cellular protein that restricts the ability of adenoviral vectors to infect cancer cells. We have demonstrated that CEACAM6 can antagonize the Src signaling pathway, downregulate cancer cell cytoskeleton proteins, and block adenovirus ...[more]

PMID: 19411761

Similar Datasets

Expression profiling of PaTu8988s and PaTu8988t cell lines

Project description:We used microarray to look at the genes deregulated in PaTu8988s (adenovirus insensitive) and PaTu8988t (adenovirus sensitive) cell lines PaTu8988s and PaTu8988t are pancreatic cell lines derived from the same patient and show significant responses to oncolytic adenoviruses. The different response to adenovirus in these cell lines is not related to the previously known mechanisms that affect adenovirus infection. The two cell lines represent represent a "suitable" model to screen tumour-associated genes affecting the potency of aoncolytic adenovirus.

2010-01-10 | GSE14701 | GEO

Paclitaxel resistance in ovarian cancer increases oncolytic adenovirus efficacy via upregulated CAR expression and dysfunctional cell cycle control

Project description:The microtubule-stabilising drug paclitaxel has activity in relapsed ovarian cancer. However, resistance frequently develops. Oncolytic adenoviruses are a novel cancer therapy, and replicate selectively within and lyse malignant cells, leading to productive infection of neighbouring cells. We found increased efficacy of adenoviruses of multiple subtypes in paclitaxel-resistant ovarian cancer cells. There was increased expression of a key adenovirus receptor, CAR (coxsackie adenovirus receptor), due to increased transcription that resulted from histone modification. Moreover, CAR transcription increased in intraperitoneal xenografts with acquired paclitaxel resistance and in tumours from patients with paclitaxel-resistant ovarian cancer. Finally, we identified dysregulated cell cycle control as a second mechanism of increased adenovirus efficacy in paclitaxel-resistant ovarian cancer and that inhibition of CDK4/6 using PD-0332991 was able both to reverse paclitaxel resistance and reduce adenovirus efficacy. Thus, paclitaxel resistance increases oncolytic adenovirus efficacy via at least two separate mechanisms.

2015-12-10 | GSE54772 | GEO

Paclitaxel resistance in ovarian cancer increases oncolytic adenovirus efficacy via upregulated CAR expression and dysfunctional cell cycle control

2015-12-10 | E-GEOD-54772 | biostudies-arrayexpress

Resistance of primary ovarian cancer cells to oncolytic adenoviruses

Project description:This SuperSeries is composed of the following subset Series: GSE15350: Resistance of primary ovarian cancer cells to oncolytic adenoviruses part1 of 2 GSE15351: Resistance of primary ovarian cancer cells to oncolytic adenoviruses part2 of 2 Refer to individual Series

2009-04-01 | E-GEOD-15473 | biostudies-arrayexpress

RNA-seq data for OMVs@P2O-Ads treated cell derived xenograft and PBS treated cell derived xenograft

Project description:Autophagy-overactivated composite microbe engineered from oncolytic adenoviruses for the cascade enhancement of cancer immunotherapy

2022-08-15 | GSE211227 | GEO

Glioma proteome organization under oncolytic adenoviral infection

Project description:Glioblastoma multiforme (GBM) is the most common and aggressive type of malignant glioma. Oncolytic adenoviruses are being modified to exploit the aberrant expression of proteins in tumor cells to enhance tumor tropism and glioma-selective replication. E1A mutant adenovirus Delta-24-RGD has shown favorable toxicity profile and remarkable efficacy in a first-in-human phase I clinical trial. However, the comprehensive modulation of glioma metabolism in response to Delta-24-RGD infection is poorly understood. Integrating mass spectrometry based-quantitative proteomics, physical and functional interaction data, and biochemical approaches, we conducted a cell-wide study of cytosolic, nuclear, and secreted glioma proteomes throughout the early time course of Delta-24-RGD infection.

2018-10-22 | PXD008022 | Pride

Modulation of glioma cell proteome by Delta-24-RGD adenovirus (48hpi)

Project description:Glioblastoma multiforme (GBM) is the most common and aggressive type of malignant glioma. Oncolytic adenoviruses are being modified to exploit the aberrant expression of proteins in tumor cells to enhance tumor tropism and glioma-selective replication. E1A mutant adenovirus Delta-24-RGD has shown favorable toxicity profile and remarkable efficacy in a first-in-human phase I clinical trial. However, the comprehensive modulation of glioma metabolism in response to Delta-24-RGD infection is poorly understood. Integrating mass spectrometry based-quantitative proteomics, physical and functional interaction data, and biochemical approaches, we conducted a cell-wide study of intracellular and secreted glioma proteomes at late stage of Delta-24-RGD infection, when prominent autophagy has been described.

2018-12-11 | PXD010256 | Pride

Modulation of glioma cell proteome by Delta-24-RGD adenovirus (24hpi)

Project description:Glioblastoma multiforme (GBM) is the most common and aggressive type of malignant glioma. Oncolytic adenoviruses are being modified to exploit the aberrant expression of proteins in tumor cells to enhance tumor tropism and glioma-selective replication. E1A mutant adenovirus Delta-24-RGD has shown favorable toxicity profile and remarkable efficacy in a first-in-human phase I clinical trial. However, the comprehensive modulation of glioma metabolism in response to Delta-24-RGD infection is poorly understood. Integrating mass spectrometry based-quantitative proteomics, physical and functional interaction data, and biochemical approaches, we conducted a cell-wide study of intracellular and secreted glioma proteomes at late stage of Delta-24-RGD infection, when prominent autophagy has been described.

2018-12-11 | PXD011580 | Pride

nuclear proteomics of glioma cells infected with an oncolytic adenovirus

2018-10-22 | PXD008023 | Pride

RNA sequencing of an optimized shuttle cell line for intranasal delivery

Project description:We generated cell lines from LX-2 hepatic stellate cells that are otpimzed for intranasal delivery of the oncolytic adenovirus XVir-N-31 to treat glioblastoma. One cell line migrates faster, the next in addition expressed HSV-TK as a safety gene to eliminate cells in case of adverse events.

2023-08-18 | GSE234262 | GEO

OmicsDI is part of the ELIXIR infrastructure

OmicsDI is an Elixir interoperability service. Learn more ›

OmicsDI Databases

PRIDE
PeptideAtlas
MassIVE
JPOST Repository
Physiome Model Repository

EGA
EVA
ENA
LINCS
PAXDB
Cell Collective

MetaboLights
Metabolomics Workbench
MetabolomeExpress
GNPS
BioModels
FAIRDOMHub

ArrayExpress
dbGaP
ExpressionAtlas
GEO
NODE

Information

Databases
Help
API
Contact us
Code on GitHub
Terms of use
Submit Data